Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.

Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.

Findings showed a 97% device success rate. In addition, serious adverse events were uncommon (less than 1%), and safety events at 30 days were favourable.

Interview Questions:
1. Could you tell us about the PASCAL System?
2. What was the study design and patient population?
3. What are the key outcomes?
4. What are the potential clinical implications of these findings?
5. What further study is needed, and what are the next steps?

Recorded remotely from Cincinnati, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographer: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on X:

Чтобы скачать видео "NY Valves 25: Early Clinical and QoL Outcomes of the PASCAL System" передвинте ползунок вправо